This article first appeared on GuruFocus.

Metropolis Healthcare Ltd (BOM:542650) is set to release its Q2 2026 earnings on Nov 6, 2025. The consensus estimate for Q2 2026 revenue is $4.10 billion, and the earnings are expected to come in at $9.20 per share. The full year 2026's revenue is expected to be $16.56 billion and the earnings are expected to be $39.08 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 2 Warning Signs with BOM:542650.

Is BOM:542650 fairly valued? Test your thesis with our free DCF calculator.

Over the past 90 days, revenue estimates for Metropolis Healthcare Ltd (BOM:542650) have increased from $16.46 billion to $16.56 billion for the full year 2026 and from $18.56 billion to $18.79 billion for 2027. Earnings estimates have seen a slight decline from $39.11 per share to $39.08 per share for the full year 2026, while for 2027, they have increased from $48.69 per share to $48.89 per share.

In the previous quarter ending on June 30, 2025, Metropolis Healthcare Ltd's (BOM:542650) actual revenue was $3.86 billion, which beat analysts' revenue expectations of $3.80 billion by 1.59%. Metropolis Healthcare Ltd's (BOM:542650) actual earnings were $8.66 per share, which missed analysts' earnings expectations of $9.20 per share by -5.87%. After releasing the results, Metropolis Healthcare Ltd (BOM:542650) was up by 0.82% in one day.

Based on the one-year price targets offered by 17 analysts, the average target price for Metropolis Healthcare Ltd (BOM:542650) is $2,157.18 with a high estimate of $2,537 and a low estimate of $1,655. The average target implies an upside of 6.16% from the current price of $2,031.95.

Based on GuruFocus estimates, the estimated GF Value for Metropolis Healthcare Ltd (BOM:542650) in one year is $2,369.17, suggesting an upside of 16.60% from the current price of $2,031.95.

Based on the consensus recommendation from 15 brokerage firms, Metropolis Healthcare Ltd's (BOM:542650) average brokerage recommendation is currently 2.4, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.